Analysts upgraded Human Genome Sciences Inc. (Nasdaq: HGSI) after the company reported surprisingly upbeat late stage drug trial results for its lupus treatment. The stock price climbed $1.33 to close at $13.84.
Human Genome Upgraded
July 21, 2009 at 17:35 PM EDT
